ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,718.57
      0.28%
      US Tech 100
      19,296.80
      0.00%
      Dow Jones
      42,124.65
      0.15%
      Brent Oil
      73.735
      -0.20%
      Bitcoin
      63,246.84
      -0.59%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Genenta Science SPA (GNTA) Quote

      Genenta Science SPA

      Genenta Science SPA (GNTA)

      NASDAQ
      3.70
      0.19
      (5.41%)
      At close: September 23 4:00PM
      Delayed by 15 minutes
      3.70
      0.00
      ( 0.00% )
      After Hours: 5:17PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      3.70
      Bid
      3.55
      Ask
      4.94
      Volume
      3,795
      3.59 Day's Range 3.9513
      0.00 52 Week Range 0.00
      Market Cap
      67.403M
      Previous Close
      3.51
      Open
      3.59
      Last Trade
      2
      @
      4.07
      Last Trade Time
      16:00:00
      Financial Volume
      $ 14,116
      VWAP
      3.7196
      Average Volume (3m)
      -
      Shares Outstanding
      18,216,958
      Dividend Yield
      -
      PE Ratio
      -6.35
      Earnings Per Share (EPS)
      -0.58
      Revenue
      465k
      Net Profit
      -10.62M

      About Genenta Science SPA

      Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's product under development includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affec... Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's product under development includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy. Show more

      Sector
      Health Practitioners, Nec
      Industry
      Health Practitioners, Nec
      Website
      www.genenta.com
      Headquarters
      Milan, Lombardy, Ita
      Founded
      -
      Genenta Science SPA is listed in the Health Practitioners sector of the NASDAQ with ticker GNTA. The last closing price for Genenta Science was $3.51. Over the last year, Genenta Science shares have traded in a share price range of $ 0.00 to $ 0.00.

      Genenta Science currently has 18,216,958 shares outstanding. The market capitalization of Genenta Science is $63.94 million. Genenta Science has a price to earnings ratio (PE ratio) of -6.35.

      Ask ADVFN Intelligence (AI)

      GNTA Latest News

      More News

      Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

      MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the...

      May 06 2024
      GlobeNewswire Inc.

      Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

      February 12 2024
      Edgar (US Regulatory)

      Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

      MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power...

      February 08 2024
      GlobeNewswire Inc.

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      October 20 2023
      Edgar (US Regulatory)

      Genenta to Present at Upcoming Scientific and Investor Conferences

      MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power...

      September 06 2023
      GlobeNewswire Inc.

      Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

      Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication MILAN, Italy and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Genenta Science...

      July 28 2023
      GlobeNewswire Inc.

      The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

      MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of...

      June 29 2023
      GlobeNewswire Inc.

      Genenta to Provide Update on Lead Product Temferon™

      MILAN, Italy and NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- Luigi Naldini, Ph.D., M.D., co-founder and Executive Scientific Board Chairman of Genenta Science S.p.A. (NASDAQ: GNTA), a...

      May 16 2023
      GlobeNewswire Inc.

      Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

      Funds available expected to be sufficient for Genenta to continue to operate into the first quarter of 2025Net exchange rate gain of €2.3 millionTax credit of €6.4 million MILAN...

      April 26 2023
      GlobeNewswire Inc.

      AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

      MILAN, Italy, July 25, 2022 (GLOBE NEWSWIRE) -- Bowling Green Bull (BGB) is an initiative to connect Italian companies, entrepreneurs and top managers aiming for international growth and...

      July 25 2022
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10000000DR
      40000000DR
      120000000DR
      260000000DR
      520000000DR
      1560000000DR
      2600000000DR

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      MSSMaison Solutions Inc
      $ 1.6801
      (134.98%)
      		10.82M
      HSCSHeart Test Laboratories Inc
      $ 4.30
      (46.26%)
      		564.55k
      LGHLWLion Group Holding Ltd
      $ 0.0084
      (31.25%)
      		57.87k
      EDUCEducational Development Corporation
      $ 2.5199
      (25.37%)
      		2.35M
      LBRDALiberty Broadband Corporation
      $ 72.92
      (21.80%)
      		95.63k
      BIVIBioVie Inc
      $ 1.36
      (-51.43%)
      		290.95k
      FRESFresh2 Group Ltd
      $ 1.55
      (-14.84%)
      		60.65k
      EJHE Home Household Service Holdings Ltd
      $ 0.091
      (-10.87%)
      		2.19M
      XPONExpion360 Inc
      $ 0.1044
      (-10.77%)
      		5.95M
      TGLTreasure Global Inc
      $ 1.08
      (-9.24%)
      		663.36k
      LUXHLuxUrban Hotels Inc
      $ 0.1019
      (10.40%)
      		15.02M
      MSSMaison Solutions Inc
      $ 1.6801
      (134.98%)
      		10.82M
      BLUEbluebird bio Inc
      $ 0.5244
      (7.26%)
      		8.61M
      CMCSAComcast Corporation
      $ 40.73
      (0.00%)
      		6.29M
      XPONExpion360 Inc
      $ 0.1044
      (-10.77%)
      		5.95M

      GNTA Discussion

      View Posts
      Awl416 Awl416 2 months ago
      What leaked
      👍️0
      Monksdream Monksdream 5 months ago
      GNTA under $3
      👍️0
      Luckypennyman Luckypennyman 2 years ago
      FDA’s decision to grant Orphan Drug Designation to Temferon









      glta
      👍️0
      makinezmoney makinezmoney 2 years ago
      $GNTA: Just got a $15 PriceTarget upgrade.

      From here $5, looks like its gonna be a nice ride up


      GO $GNTA
      👍️0
      conix conix 3 years ago
      Maxim starts Genenta Science at buy; PT $21

      Stephen Kilmer

      January 13, 2022

      Maxim Group launched coverage of Genenta Science S.p.A (NASDAQ:GNTA) with a “buy” rating and $21 price target. The stock closed at $9.94 on Jan. 12.

      Genenta is developing cancer therapeutics using an autologous ex-vivo, lentiviral-based gene therapy strategy.

      The company initially is targeting unmethylated-MGMT glioblastoma multiforme (GBM) patients with its lead gene therapy, Temferon, which is currently being evaluated in a Phase 1/2 dose-escalation study. Data from the latter two cohorts are expected around the end of 2022.

      “Tumor agnostic gene therapy, Temferon, can potentially be applied broadly to multiple cancer types because it is not tumor dependent,” writes analyst Naureen Quibria, Ph.D.

      She said lentiviral-based gene therapy is a validated approach, with treatment approvals seen in Kymriah for acute lymphoblastic leukemia and diffuse large B-cell lymphoma, Zynteglo for ß-thalassemia, and Libmeldy for metachromatic leukodystrophy.

      Genenta’s Temferon, has also demonstrated initial signals of efficacy in its Phase 1/2 clinical study in GBM, as well as robust activity in multiple tumor models in preclinical studies.

      “Though the program is somewhat early, we believe the broad utility of the platform and potential durability of the approach support a ‘buy’ rating and our $21 price target,” Dr. Quibria said.
      👍️0
      asser_al7ob asser_al7ob 3 years ago
      is this genta that we have before, it is coming back after years
      👍️0
      Phosphene Phosphene 3 years ago
      Clinical-stage biotechnology company pioneering
      the development of lentivirus-based first-in-class
      gene and cell therapies in cancer.

      Genenta uses gene-based cytokine delivery
      to activate the immune system within the tumor,
      providing a controlled, targeted and enduring anti-tumor response.

      https://www.genenta.com/

      TEM-GBM_001

      👍️0

      Your Recent History

      NASDAQ
      GNTA
      Genenta Science
      NYSE
      RCB
      Ready Capital
      Delayed Upgrade Clock